Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
A phase 3 trial of Bempegaldesleukin and Nivolumab in Melanoma, run by Nektar Therapeutics, recorded as terminated on the registry.
Overview
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence is a phase 3 interventional study registered as NCT04410445 by Nektar Therapeutics, with 765 participants recorded, started 2020-07-27 and due to reach its primary completion in 2022-09-22. Interventions recorded: Bempegaldesleukin, Nivolumab. Conditions recorded: Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin).
Linked to the drug Bempegaldesleukin because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Shares Nektar Therapeutics, Bempegaldesleukin, Nivolumab and the tag pipeline.
- TrialA Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Shares Bempegaldesleukin, Nivolumab, Melanoma and the tag pipeline.
- TrialStudy to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
- TrialABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Shares Nivolumab and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Nivolumab and the tag pipeline.
- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Nivolumab and the tag pipeline.
- TrialPhase II Trial of Ontak With Metastatic Melanoma
Shares Melanoma and the tag pipeline.